Many immunotherapies exploit such features of CD8 T cells for cancer treatment, e.g. it was suggested that the number of infiltrated CD8 T cells correlates positively with clinical outcomes in immune checkpoint blockade therapy (1). This evidence concerns the gene CD8A and cancer.